New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®.Study highlights importance of improving treatment “persistence” over time for long-term respiratory diseases. …
New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®.Study highlights importance of improving treatment “persistence” over time for long-term respiratory diseases. …
Erelzi is approved for all indications included in the reference product’s label Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine Erelzi is the second biosimilar from Sandoz to receive F…
Erelzi is approved for all indications included in the reference product’s label Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine Erelzi is the second biosimilar from Sandoz to receive F…
First-of-a-kind service for healthcare professionals will offer access to latest news from leading international transplantation congress.Transplant TODAY online service will be launched at this month’s International Congress of the Transplantation Soc…
First-of-a-kind service for healthcare professionals will offer access to latest news from leading international transplantation congress.Transplant TODAY online service will be launched at this month’s International Congress of the Transplantation Soc…
Q2 net sales were flat (0% cc[1]) as Growth Products[2] offset Gleevec generic impact Gilenya (USD 811 million, +17% cc) continued to grow double-digit mainly due to volume growthCosentyx (USD 260 million) grew strongly driven by its three approved ind…
Committee votes unanimously in favor of the Sandoz proposed biosimilar etanercept for all approved indications of the reference productCommittee’s recommendation based on totality of evidence from global development program showing biosimilar etanercep…
The EGALITY study met its primary endpoint demonstrating equivalent efficacy of Sandoz biosimilar etanercept candidate to the originator product at week 12As a first-of-its kind, the confirmatory clinical safety and efficacy study compares originator e…
Progress on biosimilar pipeline paves way for five planned launches by 2020Sandoz now plans a total of 11 biosimilar filings by end 2017 (EU and US) and has already delivered on sixInvestments of more than USD 1 billion in state of-the-art biomanufactu…